7.94
-0.05(-0.63%)
Currency In USD
| Previous Close | 7.99 |
| Open | 7.96 |
| Day High | 8.06 |
| Day Low | 7.72 |
| 52-Week High | 20.56 |
| 52-Week Low | 4.64 |
| Volume | 183,617 |
| Average Volume | 462,611 |
| Market Cap | 99.53M |
| PE | -1.45 |
| EPS | -5.49 |
| Moving Average 50 Days | 10.06 |
| Moving Average 200 Days | 9.61 |
| Change | -0.05 |
If you invested $1000 in Corbus Pharmaceuticals Holdings, Inc. (CRBP) 10 years ago, it would be worth $213.44 as of January 14, 2026 at a share price of $7.94. Whereas If you bought $1000 worth of Corbus Pharmaceuticals Holdings, Inc. (CRBP) shares 5 years ago, it would be worth $152.11 as of January 14, 2026 at a share price of $7.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 12:30 PM GMT
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will presen
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
GlobeNewswire Inc.
Dec 11, 2025 12:00 PM GMT
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
GlobeNewswire Inc.
Dec 10, 2025 9:01 PM GMT
Company will host conference call and live webcast to review and discuss the data at 8:00 am ETNORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and o